EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma

Natalie M Bath, Timothy M Pawlik

Chinese Clinical Oncology · 2023

DOI: 10.21037/cco-22-109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chinese Clinical Oncology, 2023. Verfasst von Natalie M Bath und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Antineoplastic Agents, Bile Duct Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaAntineoplastic AgentsBile Duct NeoplasmsHumansCapecitabineBile Ducts, Intrahepatic

Stichwörter der Autor:innen

Intrahepatic cholangiocarcinoma (iCCA)bile duct cancerclinical trialstargeted therapies

Substanzen

CapecitabineAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Zitieren

APA

Bath, N. M., & Pawlik, T. M. (2023). Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma. Chinese Clinical Oncology. https://doi.org/10.21037/cco-22-109

Vancouver

Bath NM, Pawlik TM. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma. Chinese Clinical Oncology. 2023. doi:10.21037/cco-22-109

BibTeX
@article{Bath2023,
  author = {Bath, Natalie M and Pawlik, Timothy M},
  title = {Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma},
  journal = {Chinese Clinical Oncology},
  year = {2023},
  doi = {10.21037/cco-22-109}
}
Kostenlos starten →